Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Four days on, three days off HIV treatment controls viral load in French pilot study

An experimental `four days on, three days off` antiretroviral regimen kept viral load fully suppressed in 96% of people for 48 weeks in a French study presented

Published
03 November 2016
By
Keith Alcorn
GSK discontinues development of maturation inhibitor BMS-986173

This is disappointing news as maturation inhibitors would expect to be active about HIV that is multi-drug resistant to HIV medicines from other classes.

Published
31 October 2016
From
HIV i-Base
Efavirenz Side Effects Include Suicide; It Could Have Been Me

I was on efavirenz for years. Within six months of dropping the drug altogether, I normalized. For the first time in years, I was not flooded with suicidal thoughts, addictions and crippling mental health woes.

Published
31 October 2016
From
The Body
Darunavir/ritonavir & lamivudine matches triple-drug therapy

Simplifying antiretroviral therapy to a two-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a three-drug regimen in

Published
31 October 2016
By
Keith Alcorn
New long-acting fusion inhibitor albuvirtide plus boosted protease inibitor matches standard triple-drug therapy

A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus two

Published
28 October 2016
By
Keith Alcorn
Tests of online PrEP purchases by London clinic find no fakes, and adequate drug levels

A sexual health clinic in central London that offered to test drug levels in users of tenofovir/emtricitabine pre-exposure prophylaxis (PrEP) who had bought it online found adequate

Published
26 October 2016
By
Gus Cairns
Two Thirds of Oral PrEP-Using MSM Would Switch to Long-Term Shots

One third of men who have sex with men (MSM) using daily oral PrEP for a year or more would "definitely switch" to a long-acting PrEP shot every 3 months, while another third would "probably switch," according to results of a 90-man survey. Hispanic and nonwhite men were significantly more likely to be among definite switchers.

Published
26 October 2016
From
NATAP
More Surprises From ÉCLAIR: Cabotegravir's 'Long Tail'

The long-acting injectable cabotegravir (ViiV Healthcare), a novel HIV prevention therapy, can persist in the body for more than a year in some people, surprising new data from the phase 2a ÉCLAIR study show. "It's an important finding because you need to give patients some sense of when that protection ends," said Jeanne Marrazzo, MD, from the University of Alabama at Birmingham.

Published
26 October 2016
From
Medscape (requires free registration)
The benefit of treatment has outweighed the clinical impact of lipodystrophy, conference hears

The 2016 International Congress on Drug Therapy in HIV Infection (HIV Glasgow) heard today that over a 20-year period, people who suffered lipodystrophy (fat redistribution) and

Published
26 October 2016
By
Gus Cairns
Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk

Insomnia, dizziness, headache and other central nervous system side-effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to

Published
25 October 2016
By
Keith Alcorn

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.